Cart
sales@molnova.com
Rigosertib
CAS No. 592542-59-1
Rigosertib( ON-01910 )
Catalog No. M24584 CAS No. 592542-59-1
Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRigosertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionRigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM).
-
DescriptionRigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition of the PI3 kinase/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in the cell cycle.
-
In Vitro——
-
In Vivo——
-
SynonymsON-01910
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|BCR-ABL|Cdk1|Flt1|Fyn|PDGFR|PLK1|PLK2|Src
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number592542-59-1
-
Formula Weight451.49
-
Molecular FormulaC21H25NO8S
-
Purity>98% (HPLC)
-
SolubilityDMSO:75 mg/mL (166.12 mM; Need ultrasonic)
-
SMILESCOC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Xu F, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signalingtransduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310.
molnova catalog
related products
-
Thrombospondin-1 (10...
Thrombospondin-1 (1016-1023) [human, bovine, mouse], a segment of Thrombospondin-1 (TSP-1), functions as a CD47 agonist.
-
MKC-1
MKC-1 is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle.
-
Pivanex
Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
